Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue: 2019-2021

  • Harmony Biosciences Holdings' Non-Current Deffered Revenue was N/A to $192,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $192,000, marking a year-over-year change of. This contributed to the annual value of $212,000 for FY2020, which is 26.13% down from last year.
  • As of Q1 2021, Harmony Biosciences Holdings' Non-Current Deffered Revenue stood at $192,000, which was down 9.43% from $212,000 recorded in Q4 2020.
  • Harmony Biosciences Holdings' 5-year Non-Current Deffered Revenue high stood at $305,000 for Q3 2020, and its period low was $192,000 during Q1 2021.
  • For the 3-year period, Harmony Biosciences Holdings' Non-Current Deffered Revenue averaged around $249,000, with its median value being $249,500 (2019).
  • Data for Harmony Biosciences Holdings' Non-Current Deffered Revenue shows a maximum YoY declined of 26.13% (in 2020) over the last 5 years.
  • Harmony Biosciences Holdings' Non-Current Deffered Revenue (Quarterly) stood at $287,000 in 2019, then declined by 26.13% to $212,000 in 2020, then reached $192,000 in 2021.
  • Its Non-Current Deffered Revenue was $192,000 in Q1 2021, compared to $212,000 in Q4 2020 and $305,000 in Q3 2020.